upadacitinib,linaclotide,risankizumab
Abbvie,ironwood pharmaceutical,Boehringer Ingelheim
['abbvie']
abbvie releases new data demonstrating breadth of its gastroenterology portfolio at 2023 digestive disease week #abbvie #breadth #data #demonstrating #digestive #disease #gastroenterology #portfolio #releases #week 
Today's News for Tomorrow's Investor
📈 Do your own DD
🇨🇦  #TSX #TSXV #CSEstocks
🇺🇸  #OTCmarkets